Bioventus extended its agreement to exclusively distribute Seikagaku’s SUPARTZ FX™ in the U.S. through May 2028. The hyaluronic acid-based product treats knee osteoarthritis pain through a 5-injection regimen.
SUPARTZ FX complements Bioventus’ joint fluid treatments HA GELSYN-3™ (3-injection) and DUROLANE® single-injection HA—the latter which received FDA premarket approval in late 3Q17.
Bioventus extended its agreement to exclusively distribute Seikagaku's SUPARTZ FX™ in the U.S. through May 2028. The hyaluronic acid-based product treats knee osteoarthritis pain through a 5-injection regimen.
SUPARTZ FX complements Bioventus' joint fluid treatments HA GELSYN-3™ (3-injection) and DUROLANE® single-injection HA—the...
Bioventus extended its agreement to exclusively distribute Seikagaku’s SUPARTZ FX™ in the U.S. through May 2028. The hyaluronic acid-based product treats knee osteoarthritis pain through a 5-injection regimen.
SUPARTZ FX complements Bioventus’ joint fluid treatments HA GELSYN-3™ (3-injection) and DUROLANE® single-injection HA—the latter which received FDA premarket approval in late 3Q17.
Copy to clipboard 
